Effect of simvastatin on endothelial function in cardiac syndrome X patients.
Patients with cardiac syndrome X with mild hypercholesterolemia were randomized to placebo (n = 20) or simvastatin 20 mg/day (n = 20). In the simvastatin group, there was a significant (26%; p < 0.0001) decrease in total cholesterol, a 38% (p < 0.0001) decrease in low-density lipoprotein cholesterol levels, and 7% a (p < 0.0001) increase in high-density lipoprotein cholesterol levels, without significant changes in triglyceride levels. Brachial artery flow-mediated dilation increased significantly (52% relative increase, p < 0.0001), and the time to > 1-mm ST-segment depression during stress testing was longer by the end of the study (p < 0.0001).
Fábián
Emília
E
Department of Cardiology, Elizabeth Hospital, Budapest, Hungary. dr.fabian.emilia@ihklinika.hu
Varga
Albert
A
Picano
Eugenio
E
Vajo
Zoltan
Z
Rónaszéki
Aladár
A
Csanády
Miklós
M
D000368:Aged; D000924:Anticholesteremic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D015444:Exercise / Q000502:physiology; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy; D008297:Male; D017566:Microvascular Angina / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000150:complications / Q000188:drug therapy; D019821:Simvastatin / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D019821:Simvastatin